| name | endo-initial-adjuvant-srl-pegvisomant-significant |
| description | This skill suggests initiating either a somatostatin receptor ligand (SRL) or pegvisomant as adjuvant medical therapy in patients with moderate-to-severe signs and symptoms of GH excess and no local mass effects following transsphenoidal surgery. Clinical triggers include postoperative IGF-1 elevation, persistent acromegalic symptoms, or residual tumor without compressive mass effect. |
Initial adjuvant SRL or pegvisomant for significant disease
STEP 1 — Gather Information
Collect postoperative IGF-1 and random GH levels, assess symptom severity (e.g., sweating, headache, fatigue), and review postoperative imaging (MRI/CT) to confirm absence of local mass effect or compressive symptoms.
STEP 2 — Rule In / Rule Out
If postoperative IGF-1 is age-normalized and symptoms are absent, consider disease in biochemical remission and no adjuvant therapy needed; if IGF-1 elevated or symptoms persist, proceed to classify disease significance.
STEP 3 — Classify or Stratify
If patient exhibits moderate-to-severe signs/symptoms of GH excess (e.g., pronounced sweating, headaches, arthralgias) without local mass effects on imaging, proceed to decide adjuvant therapy; if only modest IGF-1 elevation and mild symptoms, consider a trial of dopamine agonist (usually cabergoline) as initial adjuvant.
STEP 4 — Decide
Initiate either a somatostatin receptor ligand (e.g., octreotide LAR 20 mg monthly or lanreotide autogel 90 mg monthly) or pegvisomant (starting dose 10 mg SC daily) as initial adjuvant medical therapy based on patient preference, comorbidities, and access.
Clinical Guardrails / Mimics / Pitfalls
Do not initiate pegvisomant in patients with baseline liver dysfunction; monitor liver function tests monthly for the first 6 months and then every 6 months, discontinuing if transaminases >3× ULN. Avoid routine abdominal ultrasound for gallstone surveillance unless symptoms develop. Do not use dopamine agonist as first-line for significant disease. Ensure no local mass effect before choosing SRL/pegvisomant; if mass effect present, consider primary SRL therapy or surgery reevaluation. Monitor tumor size with MRI at 6 and 12 months after pegvisomant initiation.
Concrete Clinical Example
A 48‑year‑old woman undergoes transsphenoidal resection for a macroadenoma. Twelve weeks postoperative, IGF-1 is 1.8× ULN, she reports worsening sweating and joint pain, and MRI shows no residual tumor compressing optic chiasm or cavernous sinus. She has normal liver tests. Per this skill, she is started on octreotide LAR 20 mg monthly (or pegvisomant 10 mg daily) as adjuvant therapy.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
